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Abstract  
Alzheimer’s disease (AD) is the major cause of adult-onset dementia and 
is characterized in its pre-diagnostic stage by reduced cerebral cortical glucose 
metabolism and in later stages by reduced cortical oxygen uptake, implying 
reduced mitochondrial respiration.  Using quantitative PCR we determined the 
mitochondrial DNA (mtDNA) gene copy numbers from multiple groups of 15 or 20 
pyramidal neurons, GFAP (+) astrocytes and dentate granule neurons isolated 
using laser capture microdissection, and the relative expression of mitochondrial 
biogenesis (mitobiogenesis) genes in hippocampi from 10 AD and 9 control 
(CTL) cases.  AD pyramidal but not dentate granule neurons had significantly 
reduced mtDNA copy numbers compared to CTL neurons.  Pyramidal neuron 
mtDNA copy numbers in CTL, but not AD, positively correlated with cDNA levels 
of multiple mitobiogenesis genes.  In CTL, but not in AD, hippocampal cDNA 
levels of PGC1α were positively correlated with multiple downstream 
mitobiogenesis factors.  Mitochondrial DNA copy numbers in pyramidal neurons 
did not correlate with hippocampal Aβ1-42 levels.  After 48 hr exposure of H9 
human neural stem cells to the neurotoxic fragment Aβ25-35, mtDNA copy 
numbers were not significantly altered.  In summary, AD post-mortem 
hippocampal pyramidal neurons have reduced mtDNA copy numbers.  
Mitochondrial biogenesis pathway signaling relationships are disrupted in AD, but 
are mostly preserved in CTL.  Our findings implicate complex alterations of 
mitochondria-host cell relationships in AD. 
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Background 
 Alzheimer’s disease (AD) is the most common neurodegenerative disease 
of adults and the major cause of age-related dementia.  Memory loss first 
appears in the disorder known as “mild cognitive impairment” (amnestic MCI) that 
progresses into AD dementia at a rate of ~15% per year.  Biomarkers of MCI 
include reduced cerebral glucose accumulation with preserved oxygen uptake 
and increased brain tissue markers of oxidative stress [1, 2].  Progression into 
AD dementia is associated with further reductions of cortical glucose 
accumulation and reduced brain oxygen consumption [1, 2].  These observations 
suggest that the AD brain may be “starving” metabolically [3].   
Studies of post-mortem tissue support impaired bioenergetic metabolism 
in AD that may play a role in the degenerative loss of hippocampal and cortical 
neurons.  There is loss of activities of decarboxylase TCA enzyme complexes [2, 
4-6] and reduced mitochondrial respiration, mitochondrial mass and expression 
of mitochondrial biogenesis (mitobiogenesis) genes in post-mortem AD brain 
tissue [5, 7].  Individual AD brain neurons have impaired cytochrome oxidase 
activity histochemically [6], are populated by deleted mitochondrial DNA (mtDNA) 
molecules [8]  and have reduced expression of nuclear encoded respiratory 
genes [9] .  Loss of cerebral glucose accumulation in MCI and later in AD 
dementia and direct indicators of impaired mitochondrial function in AD brains 
could occur from lowered glucose transport, impairment of glycolysis, reduced 
activities of mitochondrial oxidative decarboxylation in the TCA cycle, impaired 
mitochondrial respiration, or combinations of these processes.   
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   Mitochondrial respiration involves many proteins encoded both from 
nuclear and mitochondrial DNA.  A complex regulatory system ensures an 
appropriate coordinated expression from both genomes for both basal respiratory 
levels or stress-induced upregulation (for review see:[10-13] ).   Nuclear 
respiratory (transcription) factors 1 and 2 (NRF1 and NRF2) activate transcription 
of nuclear-encoded respiratory genes and transcription factor A from 
mitochondria (TFAM).  TFAM initiates transcription of the mitochondrial-encoded 
respiratory genes and has a role in maintaining the mtDNA copy number and 
stabilizing the mtDNA.  Peroxisome proliferator-activated receptor gamma 
coactivator 1α (PGC1α) is a coactivator for many mitobiogenesis-associated 
transcription factors including NRF1, NRF2 and estrogen-related receptor α 
(ERRα, associated with fatty acid oxidation).  PGC1α plays a key role in 
responding to environmental changes, through both post-translational 
modifications and increased expression, to turn on mitobiogenesis [14].  Although 
the exact mechanism of how PGC1α upregulates expression of the nuclear 
transcription factors is not clear, increased expression of NRF1 and NRF2 and 
subsequent increased expression of TFAM are observed when PGC1α is 
overexpressed [15].  Additionally, PGC1α does bind with NRF1, NRF2 and ERRα 
and co-activates expression of their target genes resulting in significantly 
increased mitobiogenesis resulting in the label of the “master regulator”.   
The present study examines in more detail the status of mtDNA and the 
expression levels of select mitobiogenesis genes from post-mortem AD and 
control (CTL) tissue.  We used laser capture microdissection (LCM) to isolate 
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hippocampal pyramidal neurons, GFAP(+) glia and dentate granule neurons and 
quantitative real-time multiplex PCR (qPCR) to demonstrate decreased mtDNA 
copy number in pyramidal neurons from AD compared to control (CTL) cases.  
We show a loss of correlation of mitobiogenesis factors cDNAs in whole 
hippocampal tissue compared to mtDNA copy numbers in AD pyramidal neurons, 
which is preserved in CTL cases.  In CTL hippocampal tissue PGC1α expression 
levels significantly correlate or trend with expression of other mitobiogenesis 
genes, but this correlation is lost in AD tissue.  Total hippocampal Aβ1-42 peptide 
levels from post-mortem tissue did not correlate with mtDNA copy numbers in 
any cell type in AD.  Additionally, we could not induce the mtDNA copy number 
loss by exposing human H9 neural stem cells to the neurotoxic Aβ25-35 fragment. 
 
Methods 
Tissue/samples: Human brain tissue was obtained following autopsy and flash 
frozen.  Hippocampi were obtained from the Brain Resource Facility at the 
University of Virginia.  Cases consisted of 10 AD by clinical and pathological 
diagnosis (mean age 79.9, mean post-mortem interval 6hr, 6 female, 4 male) and 
9 CTL clinically considered normal with no pathological abnormalities (mean age 
63.2, mean post-mortem interval 8.45hr, 6 female, 3 male).  Tissue was 
embedded in Cryostat mounting media and sliced at 10 µm.  Ten to twelve slices 
were processed for RNA extraction using the miRNeasy kit from Qiagen following 
the manufacturer’s instructions.  RNA integrity was evaluated using the BioRad 
Experion capillary electrophoresis system.  RNA quality index (RQI) values were 
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between 6.7 and 9.5 [16].  Representative electropherograms are presented in 
supplemental figure 1. The RNA was converted to cDNA using BioRad i-script 
cDNA synthesis kit following the manufacturer’s instructions.  These samples are 
referred to as whole tissue cDNA.  Approximately 15 slices were processed for 
protein isolation for sandwich elisa for Aß1-42 using the kit from Invitrogen and 
following the manufacturer’s instructions.  Additional slices were melted on 
uncoated slides for laser capture microdissection of hippocampal pyramidal 
neurons, glia and dentate granule cells. 
Laser Capture Microdissection (LCM):  Slices were fixed in 70% Ethanol, 
hydrated, stained with methylene blue, dehydrated and cleared in xylene for 
identifying and capturing hippocampal pyramidal neurons and dentate gyrus 
granule cells.  Hippocampal glia were identified immunohistochemically using 
anti-GFAP (Millipore AB5804) at 1:100 followed by Alexa-488-anti-rabbit at 1:100 
for LCM (rt 1hr each).  The Arcturus XT system was used for capturing specific 
cell types.   
Quantitative real-time PCR (qPCR):  A BioRad CFX96 thermocycler was used for 
all qPCR experiments with BioRad power mix according to manufacturer’s 
recommendations for each type of experiment.  All samples were analyzed in 
triplicate.  mtDNA copy number from specific cell types (as done previously by 
our group [17]):  From pilot studies we determined that capturing 20 cells/cap 
(pyramidal neurons and GFAP+ glia) or 15 cells/cap (dentate gyrus granule cells) 
and 4 caps/case we could minimize the variability that occurs due to the 10 µm 
slice being in different planes of each cell (Supplemental Figure 2).  Caps were 
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extracted overnight at 65oC with 50µl tris buffered proteinase K for DNA 
extraction [17].  The proteinase K was heat inactivated and 200µl TE was added.  
Multiplex qPCR was used to determine gene copy number for 4 genes around 
the mitochondrial genome (12S rRNA, ND2, ND4 and COX III) from LCM isolated 
cells.  The mtDNA copy number was determined/cap of 15 or 20 cells by 
comparing to a standard curve of circular human mtDNA run on the same plate.  
The mtDNA standards were prepared as described previously [18].  Since there 
was minimal variability between the 4 genes, the average of the 4 genes was 
used to estimate mtDNA copy number/LCM cap.  Primer and probe sequences 
are listed in the Supplemental Table.  Relative gene expression from whole 
hippocampal tissue:  Whole tissue cDNA was analyzed for expression of nuclear 
encoded mitobiogenesis genes.  Relative expression of PGC-1α, NRF1, NRF2, 
TFAM and ERRα were determined using Sofast EvaGreen (BioRad) qPCR and 
primers we designed using Beacon designer software.  A panel of 6 reference 
genes was assessed using Sofast EvaGreen qPCR to determine 3 with the least 
variability across all cases.  GAPDH, 14-3-3z and CYC-1 were selected with 
GeNorm analysis in qbase PLUS (Biogazelle) and their geometric means in each 
cDNA sample were used to normalize relative expression of the mitobiogenesis 
regulatory genes.  All EvaGreen qPCR experiments included a human fetal brain 
cDNA standard curve for assessing relative expression of each gene.  Melt 
curves were run with each qPCR to ensure only a single species was being 
amplified. Specific primer sequences used are in the Supplemental Table. 
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Aß1-42 elisa:  Slices were dissolved in 5M guanidine, 50mM tris (pH 8.0) plus 
protease inhibitor cocktail (Calbiochem, set III).  Protein concentrations were 
determined using the Pierce BCA protein assay with BSA as the standard.  
Samples were diluted with 0.1M phosphate (pH7.4) to achieve 1mg/ml.  
Sandwich elisas were analyzed using 50µl of each sample in duplicate following 
the manufacturer’s protocol (Invitrogen).  Most AD cases were much higher than 
the CTLs, so they were re-analyzed shortening the time of the horseradish 
peroxidase visualization step so the high end of the standard curve and those 
samples had absorbance values within the detection limits of the 
spectrophotometer.    
Cell Culture H9 neural stem cells: Human Neural Stem Cells (H9-derived) (H9 
NSCs) were purchased from Gibco (Life Technologies) and cultured according to 
the supplier’s instructions.   Briefly, cells were grown in Knock Out DMEM/F12 
with 2 mM GlutaMax-I, 20 ng/ml basic Fibroblast Growth Factor, 20 ng/ml 
Epidermal Growth Factor, and 2% StemPro Neural Supplement in CellStart 
coated vessels.  All medium components were purchased from Life 
Technologies.  Medium was changed every 2 to 3 days and cells were kept at 
37° C in a humidified CO2 incubator.   H9 NSC cultures were maintained 
between 50 and 90% confluence.  Aβ25-35 and Aβ35-25 (Bachem, Torrance, CA) 
were diluted to 2 mM in water and aliquots stored frozen.  72 hours before 
treatment aliquots were placed at 37°C to aggregate [19].  35 mm dishes of 90% 
confluent H9 NSCs were treated with 10 uM aggregated Aβ25-35 or Aβ35-25 in 
growth medium.   After 48 hours cells were lifted with Accutase, washed, and 
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each pellet sonicated in 350 ul RLT Plus (Qiagen) with 1% 2-mercaptoethanol.  
DNA and RNA were isolated from triplicate samples for each treatment using an 
AllPrep DNA/RNA Mini Kit (Qiagen).  Genomic DNA was quantified using a 
NanoDrop 2000c.  
Statistical Analysis: All analyses were performed using the statistical software by 
GraphPad Prism.  Frequency distribution of mtDNA copy numbers determined for 
each LCM cap from the qPCR experiments were divided by the average mtDNA 
copy number/cap of the control cases for each cell type.  A frequency distribution 
of each cap as a percent of CTL was analyzed using Kolmogorov-Smirnov test 
for comparing cumulative distributions after outliers (±2xSD) were excluded.  
Between AD and CTL for each cell type a Mann Whitney non-parametric t-test 
was used to obtain p-values.  P<0.0167 was considered statistically significant.  
Correlation analyses were performed between relative expression of the 
mitobiogenesis genes as determined by obtaining the relative expression of each 
gene normalized to the average of the 3 reference genes used for each case.  A 
non-parametric Kruskal-Wallis analysis was performed to assess the correlation 
between PGC1α and the other mitobiogenesis genes from AD vs CTL cases, 
between the average mtDNA copy number/case from hippocampal pyramidal 
neurons and the normalized relative expression of the mitobiogenesis genes and 
between the Aβ42 levels/case and the average mtDNA copy numbers/case. 
 
Results  
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mtDNA gene content is reduced in AD hippocampal pyramidal neurons.  To 
determine if the mtDNA copy number was reduced in hippocampal pyramidal 
neurons, GFAP(+) astrocytes or dentate gyrus granule cells in AD cases 
compared to CTL cases, we isolated specific cell types using LCM and analyzed 
for mtDNA gene copy number for 4 genes around the mitochondrial genome 
(12S rRNA, ND2, ND4, COIII; see Methods).  Ratios of mtDNA protein coding 
genes to 12S rRNA were all ~1.0 (Supplemental Figure 3), did not suggest any 
significant level of mtDNA deletions in our populations and demonstrated that we 
were only assessing DNA (not RNA) from our extraction.  The mtDNA copy 
number reported is the average copy number of these 4 mitochondrial 
genes/LCM cap.  Mitochondrial DNA copy number values were divided by the 
mean of the CTL cases for each cell type and presented as a percentage of 
mean CTL values.  Figure 1 depicts a histogram of the fraction frequency (in bins 
of 20) of mtDNA copy number for each LCM cap as the percentage of the mean 
of the CTL group for each cell type.  The AD pyramidal neurons (Fig. 1A) are 
shifted to a larger proportion being less than 100% compared to CTL (Fig. 1B) 
indicating significantly decreased mtDNA copy numbers in hippocampal 
pyramidal neurons from AD cases (p=0.0086, non-parametric Kolmogorov-
Smirnov test).  Mitochondrial DNA copy numbers in glia from AD (Fig. 1C) were 
not statistically significantly different from CTL (Fig. 1D), although there was a 
trend towards significance (p=0.0899, non-parametric Kolmogorov-Smirnov test).   
Mitochondrial DNA copy numbers in dentate granule cells were not significantly 
different in AD compared to CTL (Fig. 1 E,F).  A t-test of the raw values of the 
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mtDNA copy numbers from hippocampal pyramidal neurons also indicated a 
statistically significant decrease of 17% (p=0.0475) in AD compared to CTL (data 
not shown). 
 
mtDNA copy number in CTL but not in AD pyramidal neurons correlates 
with cDNA levels of mitobiogenesis factors NRF2, ERRα, NRF1 and TFAM. 
To determine if the decreased mtDNA copy numbers in AD pyramidal neurons 
were related to the relative expression of the mitobiogenesis genes, we extracted 
total RNA from frozen sections of the same tissue block used for the specific cell 
isolation and generated cDNA using random hexamer priming.  The relative 
expression of each gene was normalized to reference genes with the least 
variability across all samples (See Methods).  Figure 2 shows the relatively linear 
relationships among levels of pyramidal neuron mtDNA gene copy numbers 
(average/case) and the reference-gene normalized expressions of the 
mitobiogenesis factors NRF2, NRF1, ERRα and TFAM in CTL (Fig. 2B, D, F, H), 
but not AD pyramidal neurons (Fig. 2 A, C, E, G).  PGC1α showed a trend toward 
a linear correlation, but did not reach statistical significance (Supplemental Figure 
4).  These experiments indicate that in post-mortem hippocampal tissue from 
CTL cases the relationship between mitobiogenesis factors and mtDNA copy 
number in pyramidal neurons is preserved, whereas this relationship is lost in AD 
cases. 
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Mitobiogenesis signaling relationships are preserved in CTL but not AD 
hippocampi. To determine if the relationship between PGC1α, the “master” 
upstream co-activator of mitobiogenesis signaling factors, and expressions of 
NRF1, NRF2, TFAM and ERRα were preserved in each case, we evaluated the 
correlation between the relative expression of PGC1α and each of the other 
genes/case.  Figure 3 depicts the significant correlation between PGC 1α and 
NRF2 and ERRα in CTL cases (Fig. 3B & H,p=0.017 and 0.021, respectively), 
but not in AD cases (Fig.3A & G;).  NRF1 also showed a positive trend in CTL 
cases (Fig. 3D), but did not reach statistical significance (p=0.085).  In both AD 
and CTL, TFAM trended toward a correlation with PGC1α (p≈0.2).  These 
experiments indicate the correlation between the master regulator PGC 1α and 
the downstream mitobiogenesis factors in post-mortem tissue is preserved in 
CTL cases, but lost in AD cases.    
 
mtDNA copy number does not correlate to Aβ(1-42) levels.  To determine if 
Aβ1-42 levels were related to the decreased mtDNA copy numbers in AD 
pyramidal neurons we prepared whole tissue homogenates from the same tissue 
blocks used to isolate specific cell types and analyzed for Aβ1-42 levels using a 
sandwhich elisa.  Figure 4 shows the lack of correlation of mtDNA gene levels in 
isolated pyramidal neurons, GFAP (+) astrocytes and dentate gyrus granule cells 
compared to Aβ1-42 levels in AD.  Interestingly, CTL hippocampal Aβ1-42 levels 
positively correlated with the pyramidal neuron mtDNA copy number from each 
case (p=0.0038; two cases had moderate Aβ1-42 levels).  This correlation must be 
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viewed in the context that it is being driven by the two CTL cases with moderately 
elevated Aβ1-42 levels.  Additional correlations of Aβ1-42 levels with mitobiogenesis 
gene expression levels were also not significant in AD cases.  However CTL 
cases showed significant correlations with Aβ1-42 and NRF1 and ERRα and close 
to significance (p=0.055) for NRF2 (Supplemental Figure 5).   The lack of 
correlations in the AD cases may be skewed by the one AD case with low Aβ1-42 
levels. 
  
Exposure of human H9 neural precursor cells to neurotoxic Aβ25-35 does not 
reduce mtDNA gene copy number.  To determine if we could induce the 
decreased mtDNA copy number we observed in post-mortem AD tissue, we 
attempted to replicate in a non-tumor, human neural stem cell model the loss of 
mtDNA copy number observed in LCM-isolated AD hippocampal pyramidal 
neurons.  Human H9 neural stem cells (derived from a hESC line) were exposed 
to 10 µM neurotoxic Aβ25-35 fragment for 48 hrs and ~50% loss of cells was 
observed.  Figure 5 shows that this treatment did not significantly alter mtDNA 
copy numbers when compared to vehicle treated cells or cells treated with the 
inverse sequence Aβ35-25. 
 
Discussion 
 In our postmortem AD hippocampi we found that mtDNA gene copy 
numbers were significantly reduced in surviving pyramidal neurons compared to 
identical cell types in CTL hippocampi.  This is consistent with the observation of 
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reduced mtDNA copy numbers in whole hippocampi [7] and cortex [20] from AD 
cases.  However, Hirai, et al., [21] using in situ hybridization detected increased 
mtDNA in hippocampal pyramidal neurons from AD cases compared to CTL; 
from EM photos they determined many of these were in lipofuscin vacuoles and 
are likely from degrading mitochondria.  Additionally, they did not detect mtDNA 
differences in the glia or granule cells by in situ hybridization, which is consistent 
with our observations in those cell types.  They also comment that using PCR 
techniques, they did not detect an overall difference in mtDNA in AD compared to 
control tissue.  Our cells were isolated by laser capture and only intact cells were 
selected, which could explain the difference between our study and their study.  
Another factor that could be contributing to the decreased mtDNA copy number 
in AD in our study is that the control cases were younger (~16yr) than the AD 
cases.  Our group has previously demonstrated dramatically decreased (~90% 
loss) mtDNA copy numbers in whole brain tissue from 21 month old mice 
compared to 5 month old mice [22].  Since our samples were isolated from 
selected intact cells, we would not expect as dramatic a difference due to age as 
is observed in whole tissue studies.  A comparison of mtDNA copy number/LCM 
cap or mitobiogenesis genes versus age revealed no correlation in either AD 
cases or CTL cases in our cohort of samples (Supplemental Figure 6).   
Additionally, unknown factors about the individual’s pre-mortem status, such as 
medications they may have been on, could also have affected the mtDNA copy 
number values we determined.    
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Recently, cell-free mtDNA copy numbers in cerebral spinal fluid (CSF) 
from AD subjects, asymptomatic at risk subjects and pre-symptomatic subjects 
with a pathogenic PSEN1 mutation have been shown to be markedly reduced 
compared to age matched control subjects, non-pathogenic PSEN1 mutation 
family members, or individuals with a different dementia pathology (FTLD), 
These findings indicate that the reduced mtDNA copy numbers both occur prior 
to clinical symptoms appearing in AD and appear to be selective for AD dementia 
[23].  The same authors reported that levels of mtDNA were reduced in cortical 
neurons derived from a transgenic (APP/PS1) mouse model of familial AD.  They 
conclude that reduced CSF mtDNA levels appear to be a robust biomarker for 
pre-AD dementia.  They also suggest that the significant loss of mtDNA copy 
numbers we observed in hippocampal pyramidal neurons and nearly significant 
loss of mtDNA in GFAP(+) astrocytes have clinical correlates in CSF and may 
represent early pathogenic events in AD. 
Previous studies from our group have demonstrated decreased mRNA 
expression of mitochondrial encoded genes in cortical AD tissue homogenates 
from the same tissue sources used in the present study [5].  Decreased mRNA 
expression of many of the mitobiogenesis genes (PGC1α, NRF1, TFAM, POLγ 
and PPRC1) were also detected in the cortical AD tissue homogenates 
compared to CTL [5].  In hippocampal tissue homogenates from AD cases, 
Sheng, et al., [7] observed decreased mitobiogenesis protein levels compared to 
control tissue (PGC1α, NRF1, NRF2α, NRF2β and TFAM).  Subsequently, when 
they stably knocked down PGC1α in a cell culture line, they observed the 
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expected decreases in protein levels as well as reduced mtDNA levels relative to 
nuclear DNA levels by about 50% [7], supporting the regulatory hierarchy of 
PGC1α upregulating NRF1 and NRF2 leading to increased levels of TFAM and 
subsequently increased mtDNA levels.  Our decrease in mtDNA copy number in 
AD cases was not quantitated the same way as Sheng, et al. [7] and our 
decreased AD pyramidal neuron mtDNA copy number was not as dramatic as in 
their cell culture.  Our results, obtained from laser-captured, postmortem AD 
pyramidal neurons complement those Sheng, et al., [7] obtained in cell culture.   
We also observed a trend towards decreased mtDNA copy number in 
laser-captured GFAP(+) glia.  Even though it only approached statistical 
significance, it does demonstrate that the glia, while not thought to be affected in 
AD, may in fact also be metabolically impaired and contribute to the deficits other 
groups observe in whole tissue homogenates.  Additionally, we observed no 
difference in mtDNA copy number in dentate gyrus granule cells, suggesting that 
they may not be bioenergetically altered in AD, and adding cell specificity to our 
findings in pyramidal neurons.  However, we cannot confirm bioenergetic status 
in individual post-mortem cells isolated by LCM.  Additionally, since we only 
selected healthy appearing cells, we cannot speculate what may be occurring in 
unhealthy or dying cells or what may have led to the death of cells no longer 
available for sampling. 
 We uncovered a more generalized defect in AD hippocampi, that of a 
dysregulation of mitochondrial biogenesis signaling.  Using pyramidal neuron 
mtDNA copy number as an indicator of mitobiogenesis, we found in CTL 
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hippocampi generally linear relationships between expression of upstream 
mitobiogenesis genes (NRF2, NRF1, TFAM and ERRα) and mtDNA gene copy 
numbers.  The relationship between CTL pyramidal neuron mtDNA copy 
numbers and PGC1α expression levels trended towards significance.  Since 
PGC1α activity can also be modulated through post-translational modification, its 
mRNA levels represent only one level of regulation (transcriptional) that may 
have limited correlation with the expression levels of the other mitobiogenesis 
genes or with the mtDNA copy numbers.   These data indicate that in control 
tissue from autopsy cases the hierarchy of mitobiogenesis regulation appears to 
be intact.  However, in AD tissue this correlation was missing, supporting the 
idea of impaired mitobiogenesis in AD as purported by others [5, 7].  Microarray 
analysis of LCM isolated hippocampal pyramidal neurons from AD cases has 
shown decreased expression of nuclear encoded respiratory genes, which is also 
consistent with impaired mitobiogenesis [9].   
 We also found in CTL, but not AD, hippocampal cDNA significant linear 
relationships among expression of the “master” mitobiogenesis regulator PGC-1α 
and multiple downstream mitobiogenesis factors it co-activates (NRF2 and 
ERRα) and a trend towards significance in others (NRF1) [11, 12].  Due to the 
heterogeneity of human samples, had our n values been larger, we may have 
achieved better correlations between all the mitobiogenesis genes expression 
levels. These studies also support an intact mitobiogenesis hierarchy in CTL 
autopsy tissue that is lost in AD tissue.  Future studies will examine this 
relationship specifically in pyramidal neurons.    
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A significant correlation between PGC1α and two key metabolism related 
proteins (pyruvate dehydrogenase A1 and complex III subunit UQCRH) has been 
demonstrated in skeletal muscle biopsies from diabetics (type II), and those with 
and without a family history of diabetes mellitus [24].  In a model of muscle 
disuse atrophy, Cassano, et al., [25]  demonstrated the expression level of 
PGC1α significantly correlated with both NRF1 and TFAM levels in the muscle 
atrophy acetyl-L-carnitine–treated animals, but only with TFAM in the non-treated 
control group.  Thus, mitobiogenesis factors seem to maintain their hierarchal 
correlation in other diseased tissues, while in AD hippocampal tissue it does not.   
The origins of this substantial dysregulation of mitobiogenesis signaling in 
AD are not clear from our experiments, likely are multifactorial and may have 
different molecular origins among the AD cases.  PGC-1α mRNA and protein 
have been reported to be decreased in AD brain, suggesting that dysfunction of 
mitobiogenesis may be the origin of mitochondrial dysfunction observed by 
several groups [5, 7].  Speculation as to potential mechanisms of mitobiogenesis 
disruption would incorporate many potential etiologies and is beyond the scope 
of this discussion.  Future studies will investigate the potential role epigenetic 
regulation may be playing. 
 While some studies correlate Aβ1-42 levels with AD pathology, we found no 
correlation of Aβ1-42 levels to the mtDNA copy number reductions in hippocampal 
pyramidal neurons, glia or dentate granule cells from AD cases, which is similar 
to what our group found previously in cortical tissue homogenates [5].  Our 
limited experiments with exposure of H9 neural stem cells to Aβ25-35 peptide do 
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not support a primary role for Aβ peptide mediating loss of mtDNA gene copy 
numbers acutely.  However, the limitations of this experiment include using a 
more neurotoxic fragment and not Aβ1-42 peptide itself, and short incubation times 
that were necessary given the degree of cell death produced in 48 hrs by Aβ25-35 
peptide.  Longer term exposure of human neurons to Aβ1-42 peptide, particularly 
oligomers at low concentrations, will help test the hypothesis that Aβ1-42 peptide 
is a pathogenic factor in loss of mtDNA genes.  Future studies will examine this 
relationship in these human neural stem cells after they have been differentiated 
into neurons. 
Our findings show that maintenance of normal mtDNA gene levels within 
individual pyramidal neurons or astrocytes is defective in AD, and that 
mitobiogenesis signaling at the transcriptome level is preserved in CTL but not 
AD hippocampi.  Whether mitobiogenesis signaling is also disrupted in 
vulnerable AD pyramidal neurons remains to be studied by LCM approaches. 
Because post-mortem studies can only find correlations and not test causal 
mechanisms, our findings support but do not prove the concept that abnormal 
mitobiogenesis signaling and disrupted downstream responses contribute to 
metabolic deficiencies observed in AD and may be primarily pathogenic.   
Furthermore, our cohort of samples is small and displays considerable variability, 
therefore we caution against generalizing our results to the sizable population of 
AD sufferers.   
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Figure Legends: 
Figure 1.  Mitochondrial DNA copy numbers in genomic DNA isolated from 
groups of 20 pyramidal neurons, 20 GFAP(+) astrocytes or 15 dentate gyrus 
granule cells from AD or CTL hippocampal sections.  Shown are histogram 
distributions of mtDNA copy numbers (average of gene copy number of 12S 
rRNA, ND2, COX III and ND4) expressed as a % of mean CTL mtDNA copy 
number levels.  Approximately 4 caps of 15-20 cells each were isolated/case.   
 
Figure 2. Relationships among mtDNA copy numbers in genomic DNA isolated 
from groups of 20 hippocampal pyramidal neurons isolated from AD or CTL and 
expression of NRF2, NRF1, TFAM and ERRα.  cDNA in whole hippocampal 
tissue samples from same tissues.  Linear regression lines and 95% confidence 
intervals are shown on each graph. 
 
Figure 3. Relationships among expression levels of PGC1α and the expression 
of other mitobiogenesis factors NRF 2, NRF 1, TFAM and ERRα from AD or CTL 
hippocampal tissue samples.  Linear regression lines and 95% confidence 
intervals are shown on each graph. 
 
Figure 4.  Relationships between Aβ1-42 peptide levels in hippocampal tissue and 
mtDNA copy numbers in pyramidal neurons, GFAP(+) astrocytes and dentate 
gyrus granule cells from AD or CTL hippocampi.  Linear regression lines and 
95% confidence intervals are shown on each graph. 
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Figure 5. Effect of 48 hrs of treatment of human neural precursor cells with 
vehicle, 10µM Aβ25-35 or 10µM Aβ35-25 on mtDNA copy number.  Values are +/- 
SEM. 
 
Supplemental Figure 1.  Pilot studies demonstrating a linear response from 
different numbers of hippocampal pyramidal neurons captured/LCM cap. 
 
Supplemental Figure 2.  Representative electropherograms demonstrating RNA 
quality with RQI values 7.7 (upper) and 9,5 (lower) 
 
Supplemental Figure 3.  Mean mtDNA gene copy numbers of the 4 genes 
assessed per LCM cap +/- SEM.  There is much greater variability in mean of the 
3-6 caps/case (adjacent same colored bars) than in the mean of the 4 genes 
averaged/cap as demonstrated by the very small SEM values.  
 
Supplemental Figure 4.  Relationships among mtDNA copy numbers in genomic 
DNA isolated from groups of 20 hippocampal pyramidal neurons isolated from 
AD or CTL and expression of PGC1α.  cDNA in whole hippocampal tissue 
samples from same tissues.  Linear regression lines and 95% confidence 
intervals are shown on each graph. 
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Supplemental Figure 5.  Relationships between Aβ1-42 peptide levels and 
expression of NRF1, NRF2, TFAM and ERRα in AD and CTL hippocampal tissue 
samples.  Linear regression lines and 95% confidence intervals are shown on 
each graph. 
 
Supplemental Figure 6. Correlation between mtDNA copy number and relative 
mitobiogenesis gene expression from AD and CTL cases vs age.  
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Supplemental 
Table 
  ND2 probe [6-FAM]CACGCAAGCAACCGCATCCATAAT[BHQ1a-Q] 
 ND2 FP AAGCTGCCATCAAGTATTTCC 
 ND2 RP GTAGTATTGGTTATGGTTCATTGTC 
 
 
 
 COX3 probe [5TET]CGAAGCCGCCGCCTGATACTG[BHQ1a-Q 
 COX3 FP TTTCACTTTACATCCAAACATCAC 
 COX3 RP CAATAGATGGAGACATACAGAAATAG 
  
 
 ND4 probe [AminoC6+TxRed]AGCCAGAACGCCTGAACGCAG[BHQ2a-Q] 
 ND4 FP TGGCTATCATCACCCGATG 
 ND4 RP GGTGTTGTGAGTGTAAATTAGTC 
  
 
 
 12SrRNA PROBE [Cy5]CGCCAGAACACTACGAGCCACAG[BHQ3a-Q] 
 12SrRNA FP CCTCAACAGTTAAATCAACAAAAC 
 12SrRNA RP CTGAGCAAGAGGTGGTGAC 
 
    POLg FP TGGTCAAACCCATTTCACTG 
 
 
RP AGAACACCTGGCTTTGGG 
 
    ERRa FP CTTCGCTCCTCCTCTCATC 
 
 
RP CTGGAGTCTGCTTGGAGTTAT 
 
    NRF1 FP TTTGTATGCCTTTGAAGAT 
 
 
RP AACCTGGATAAGTGAGAC 
 
    NRF2 FP GTTACAACTAGATGAAGAGACA 
 
 
RP ATCCACTGGTTTCTGACT 
 
    TFAM FP AATCTGTCTGACTCTGAA 
 
 
RP CACATCTCAATCTTCTACTT 
 
    PGC1a FP GATGTGAACGACTTGGAT 
 
 
RP TTGAAGGCTCATTGTTGTA 
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